Sorrento Therapeutics is a clinical stage and commercial biopharmaceutical company that delivers therapies to address unmet medical needs. Co. has programs assessing the use of its technologies and products in autoimmune, inflammatory, viral and neurodegenerative diseases. Co.'s segments are: Sorrento Therapeutics, which includes Sofusa®, a drug delivery technology that delivers biologics into the lymphatic system, and resiniferatoxin, a non-opioid-based neurotoxin in clinical trials for late stage cancer pain and moderate to severe osteoarthritis of the knee pain; and Scilex, which includes ZTlido, a lidocaine topical system for the relief of pain associated with post-herpetic neuralgia. We show 42 historical shares outstanding datapoints in our coverage of SRNE's shares outstanding history.
Understanding the changing numbers of SRNE shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SRNE versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SRNE by allowing them to research SRNE shares outstanding history
as well as any other stock in our coverage universe. |
Free SRNE Email Alerts:
Video: Shares Outstanding Importance
